- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06093815
Prospektive Studie zur Bewertung der Gewebereaktionen nach der Injektion mit biostimulatorischen Produkten
Prospektive, kontrollierte Vergleichsstudie an einem einzigen Standort zur Identifizierung und Bewertung von Gewebereaktionen nach der Injektion verschiedener biostimulatorischer Produkte
The objective of this study is to identify and assess in vivo tissue responses after injection with various biostimulatory products at various timepoints. The study will also provide tissue specimens which will be used in a subsequent study.
Safety endpoint: incidence of adverse events.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The objective of this study is to identify and assess tissue responses after injection with various biostimulatory products that are already used in the market and have CE approval. The study will assess in vivo tissue responses and provide tissue specimens which will be used in a subsequent study, under a separate protocol.
Assessments under this protocol will include ultrasound of in vivo tissue.
Safety endpoint: incidence of adverse events.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
-
Marbella, Spanien
- Ocean Clinic - Av. Ramon y Cajal 7, 29601
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Healthy male & females; 22 to 65 years of age.
- Voluntary participation
- Ability to comprehend and provide informed consent.
- Participants agree NOT to use any topical agents or products that will induce skin peeling or change the appearance of the skin in the treatment area, during the study period.
- Participants agree NOT to undergo any aesthetic treatments that influence the appearance of the skin in the treatment area during the study period.
- Participants agree NOT to undergo any surgical treatments in the treatment area during the study period.
- Participants agree NOT to take part in another clinical study or undergo other treatments during the study period.
Exclusion Criteria:
- Any previous surgery in the abdominal area.
- Any previous treatment in the abdominal area.
- Planning to receive treatment of any kind in the abdominal area.
- Acute inflammatory process and/or infection at the injection site.
- Treatment of skin area with dermatosis.
- Eczema, exanthema or open wounds.
- Previous application of over the counter or prescription, oral or topical, anti-wrinkle or skin enhancer products on the abdominal skin within the past 3 months unless allowed by the study and is continued throughout the study.
- Any contraindication to treatment with biostimulatory products based on the product's IFU.
- Previous pregnancy or intending to become pregnant during study participation.
- Known hypersensitivity to biostimulatory products or any of their formulation ingredients.
- Allergic reaction to topical and local anesthetics.
- Currently using anticoagulant therapy.
- Haemophilia / bleeding disorder.
- Chemotherapy, radiotherapy or high doses of corticosteroids.
- Systemic infection (e.g., hepatitis).
- Uncontrolled diabetes mellitus.
- Any medical condition that may put the participant at increased risk with exposure to biostimulatory products.
- Any medication that might modulate the immune response.
- Any other illness or condition that, in the opinion of the investigator, would mean that study participation was not in the best interest of the prospective participant.
- Is a female of childbearing potential and not using medically effective birth control or is pregnant or lactating.
- Any serious disease or disorder (medical or psychiatric) that could, in the opinion of the investigator, interfere with the safe completion of treatment according to this protocol or with study.
- Injection of local anesthesia into the flap during abdominoplasty surgery.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Grundlegende Wissenschaft
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Arm 1
Subjects in Arm 1 will receive injections of biostimulatory products (Radiesse(+) undiluted, Radiesse diluted 1:1, Radiesse diluted 1:2, Sculptra, Ellanse, HArmonyCa) at 3 timepoints (six months, three months and two weeks) prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Experimental: Arm 2 - Radiesse Classic (1:1 Dilution)
Five participants in Arm 2 will receive Radiesse Classic diluted 1:1 with sterile saline (CaHA-CMC 1:1) and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
|
Experimental: Arm 2 - Sculptra
Five participants in Arm 2 will receive Sculptra diluted with 5 mL of sterile saline and saline control injections at separate predefined abdominal injection sites. All injections will be administered at a single protocol-defined timepoint, 6 months prior to removal of redundant abdominal tissue. |
A pre specified amount will be injected in tissue at selected timepoints |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Arm 1 - Ultrasound Analyses - Skin Thickness (mm)
Zeitfenster: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Elastosis
Zeitfenster: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 1 - Ultrasound Analyses - Microvascular Formation
Zeitfenster: 6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at the injection site and reported according to the study-defined category/grade. |
6 months, 3 months and 2 weeks prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Skin Thickness (mm)
Zeitfenster: 6 months prior to surgery timepoint(s)
|
Ultrasound of injection site tissue analyses (dermal thickness (mm)) |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Elastosis
Zeitfenster: 6 months prior to surgery timepoint(s)
|
Elastosis assessed by ultrasound at the injection site and reported according to the study-defined ultrasound elastosis category/grade |
6 months prior to surgery timepoint(s)
|
|
Arm 2 - Ultrasound Analyses - Microvascular Formation
Zeitfenster: 6 months prior to surgery timepoint(s)
|
Microvascular formation assessed by ultrasound at injection site and reported according to the study-defined category/grade. |
6 months prior to surgery timepoint(s)
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Safety Assessment
Zeitfenster: through study completion, an average of 6 months
|
Any patient- or investigator-observed adverse event |
through study completion, an average of 6 months
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Studienleiter: Ann P Marx, MD, Merz North America, Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Pathologische Prozesse
- Chemisch induzierte Störungen
- Arzneimittelbedingte Nebenwirkungen und Nebenwirkungen
- Extravasation von diagnostischem und therapeutischem Material
- Pathologische Zustände, Anzeichen und Symptome
- Reaktion an der Injektionsstelle
- Therapeutika
- Routen der Arzneimittelverwaltung
- Arzneimitteltherapie
- Injektionen
Andere Studien-ID-Nummern
- M900311010
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
individual data will be summarized for analyses
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .